Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatment of type 2 diabetes mellitus.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 39.00 | |
10 mg | In stock | $ 55.00 | |
25 mg | In stock | $ 82.00 | |
50 mg | In stock | $ 97.00 | |
100 mg | In stock | $ 143.00 | |
200 mg | In stock | $ 209.00 | |
500 mg | In stock | $ 358.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 48.00 |
Description | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM. Ertugliflozin L-pyroglutamic acid can be used for studies about the treatment of type 2 diabetes mellitus. |
Targets&IC50 | SGLT2 (human):0.877 nM |
In vitro | Ertugliflozin L-pyroglutamic acid demonstrated >2000-fold selectivity for SGLT2 over SGLT[2]. |
In vivo | The oral administration of Ertugliflozin L-pyroglutamic to rats acid showed concentration-dependent glucosuria[2]. |
Synonyms | PF-04971729 L-pyroglutamic acid |
Molecular Weight | 566 |
Formula | C27H32ClNO10 |
CAS No. | 1210344-83-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (220.85 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ertugliflozin L-pyroglutamic acid 1210344-83-4 GPCR/G Protein Others SGLT inhibit Sodium-dependent glucose cotransporters Inhibitor Ertugliflozin L pyroglutamic acid PF-04971729 L-pyroglutamic acid Ertugliflozin Lpyroglutamic acid inhibitor